Evaluation of quality of life in adult patients with MS switching from injectable therapy i.e. Interferon (Avonex, Betaseron, Extavia, Rebif) or Copaxone® (glatiramer acetate) to oral medication Gilenya® (fingolimod) and their caregivers
ID Number 13-1069Principal Investigator(s)
Aliza B Ben-Zacharia
Department(s) or Division(s)
The purpose of this study is to gather information on how the quality of life for people with relapsing MS who are taking an injectable form of medication for their MS is affected by switching to the oral medication Gilenya. Volunteers may qualify for this research if they have relapsing MS (or are caring for someone with MS) and are planning to switch from an injectable medication to Gilenya.
Recruiting Patients: Yes